CJC-1295 and ipamorelin are the classic "paired" peptides in growth-hormone research — and the reason they're paired is exactly that they're different. Each pulls a separate lever on the same system. Understanding the two levers is the whole comparison.

The one-line difference

Your body has two ways to trigger a growth-hormone pulse. CJC-1295 copies one of them (the GHRH "release" signal). Ipamorelin copies the other (the ghrelin trigger). Different buttons, same machine.

Two mechanisms, one system

CJC-1295Ipamorelin
ClassGHRH analogGhrelin-receptor (GHS) agonist
Lever it pullsGHRH receptorGHS/ghrelin receptor
Reported half-lifeDays (DAC form)~2 hours
Evidence baseHuman pharmacokinetic dataMostly preclinical
Defining traitLong-actingSelective (clean hormone profile)
  • CJC-1295 mimics growth-hormone-releasing hormone (GHRH) — the brain's direct "release growth hormone" order. In its DAC form it's engineered to last for days1 (the crucial DAC detail is in CJC-1295 DAC vs no-DAC).
  • Ipamorelin activates the ghrelin/GHS receptor — a separate trigger — and is prized for doing so "selectively," without the cortisol spike older peptides caused2.

Because they pull two different levers, the research rationale for combining them is complementary, not redundant: two triggers together can produce a bigger, more natural growth-hormone pulse than either on its own.

What the studies actually found

Note the model — and how uneven the evidence is between the two:

StudyModelKey resultYear
Raun et al.2Rat, pig + cells (ipamorelin)Released growth hormone as strongly as GHRP-6 but without raising cortisol — the "selective" result1998
Teichman et al.1Human (healthy adults, CJC-1295 DAC)A single injection raised growth hormone for 6+ days and IGF-1 for 9–11 days; half-life 5.8–8.1 days2006

In plain terms: CJC-1295 has been measured in people; ipamorelin's headline evidence is from animals. That's an honest asymmetry worth knowing before treating the pair as equally proven.

The half-life mismatch

This is the most practical contrast. CJC-1295 (DAC) persists for days; ipamorelin clears in ~2 hours. So even when studied as a pair, they behave on completely different timelines — ipamorelin a brief pulse, CJC-1295 a days-long background (CJC-1295 curve, ipamorelin curve).

Ipamorelin2 hBPC-1575 hHCG33 hTB-5003 dTirzepatide5 dSemaglutide7 dTest. cypionate8 d
Fig. Reported half-lives span three orders of magnitude — from a couple of hours to over a week — which is why some compounds are dosed daily and others weekly. Bars are log-free linear; values are population estimates from the cited literature.

The honest bottom line

The mechanistic pairing is real and sensible: two complementary levers on the growth-hormone system. But keep two facts in view — the evidence is uneven (human PK for CJC-1295, preclinical for ipamorelin), and neither is an approved medicine; both sit inside the FDA's ongoing 503A compounding review3. No completed human trial has tested the combination for a specific benefit.

Where to go deeper

What is CJC-1295, what is ipamorelin, and the broader growth-hormone secretagogues explainer cover each mechanism in full.